Outstanding Benefits for Patients
DIFFICULT CANCERS REQUIRE SMARTER STRATEGIES
- Tumors have latent vulnerabilities that can be identified through ETA.
- Agnostic to stage, grade, anatomy or morphology.
- Integrational multi-analyte interrogation of tumor interactome and tumor function.
- Tandem targeting of multiple vulnerabilities of the tumor using combination therapies to yield additive or synergistic benefits.
Who will Benefit
✓First-line therapy has failed.
✓Risk of therapy failure is high.
✓Cancer has relapsed.
✓For newly diagnosed patients to explore best therapy options.
✓Cancer is high-grade / metastatic.
See the Results for Yourself
Patients who have not benefited from chemo-therapy require ultra-personalized treatment. We specialize in providing guidance for difficult cases by using highly sophisticated molecular analysis technology. We have a clinically proven track record of extremely high success.
Conventional versus Modern
Exacta® is an intensive and in depth tumor gene expression analysis. It analyses 100s of millions of data points at the molecular level to reveal all possible targets for precision drugs. Exacta® is one of the most powerful tumor investigation and is an extreme analytical tool that reveals the driven mutations and pathways driving a personʼs cancer. Exacta® is best molecular analysis for difficult cancers.
✓Determines deepest genetic facets of an individual patientʼs cancer.
✓Accurate, multi-coordinate analysis of all 22,000 genes in the cancer genome.
✓Reaches the depths of cancerʼs mechanism through 100ʼs of millions of data points.
✓Reveals mutations and pathways that are propelling a particular cancer in an individual.
✓Enables a highly sophisticated treatment strategy beyond conventional perspective.
Clinically Validated (Publications)
The validation data for Exacta® / The resilient protocol has been extensively published in leading peer reviewed journals.
FREQUENTLY ASKED QUESTIONS
What is therapy recommendation?
During Exacta® analysis, the samples submitted by the patient (e.g., fresh tissue, FFPE blocks, blood, fluids) are analysed to identify vulnerabilities of cancer, for which various drugs may exist. Based on the established efficacy and safety profile, a preference list of these drugs (single drug or combinations) is assigned for each patient. This is therapy recommendation and is included as an integral part of every Exacta® report.
If two patients have the same histopathological cancer type, and one of them undergoes Exacta® analysis, can the other patient receive the same treatment as indicated in the therapy recommendation of the first patient?
It is not advisable to do that. Just as each patient is unique, so is each cancer. No two patients’ cancers are alike. Even two similar patients (e.g., age, gender, height, lifestyle) with the same type of cancer (e.g., Lung) will have different molecular profiles of tumors. Hence, each patient will receive a unique therapy recommendation.
How is the therapy recommendation used?
Therapy recommendation is not a prescription. It is a patient-specific recommendation of drugs and drug combinations with a higher potential for success. Based on the therapy recommendation, as well as information from the complete Exacta® report – the treating oncologist must evaluate the suitability of the therapy choice(s) as well as the health and fitness of the patient and make a final treatment decision. The selected treatment must be administered only under the supervision of the treating oncologist.
Why is it important to start treatment immediately?
Cancers can be very aggressive and may evolve rapidly, and the tumour profile can change dramatically over time. Starting the treatment immediately is essential as it is the best strategy to counter the aggressiveness of cancer. If there is a long enough delay, cancer may gain resistance to treatments, and re-analysis may be required.
What kind of drugs will be suggested in the therapy recommendation?
The therapy recommendation will include only those drugs which have been approved by the FDA for use – in a patient’s or another cancer type, as well as those drugs that are used to treat non-cancerous conditions. Investigational anti-cancer drugs will never be recommended.
Are there any follow-up molecular tests to assess the result of the recommended therapy?
Liquid biopsy permits real-time high-frequency monitoring of disease status and response to treatment. It effectively identifies signs of recurrence or emergent chemoresistance, as well as newer vulnerabilities of the tumor. This information empowers the treating clinician to make appropriate therapeutic course corrections in real-time to benefit the quality of life plus overall and progression-free survival.
DOWNLOAD BROCHURE + SAMPLE REPORT